Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

231 results about "Survivin" patented technology

Survivin, also called baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5, is a protein that, in humans, is encoded by the BIRC5 gene. Survivin is a member of the inhibitor of apoptosis (IAP) family. The survivin protein functions to inhibit caspase activation, thereby leading to negative regulation of apoptosis or programmed cell death. This has been shown by disruption of survivin induction pathways leading to increase in apoptosis and decrease in tumour growth. The survivin protein is expressed highly in most human tumours and fetal tissue, but is completely absent in terminally differentiated cells. These data suggest survivin might provide a new target for cancer therapy that would discriminate between transformed and normal cells. Survivin expression is also highly regulated by the cell cycle and is only expressed in the G2-M phase. It is known that Survivin localizes to the mitotic spindle by interaction with tubulin during mitosis and may play a contributing role in regulating mitosis. The molecular mechanisms of survivin regulation are still not well understood, but regulation of survivin seems to be linked to the p53 protein. It also is a direct target gene of the Wnt pathway and is upregulated by beta-catenin.

Multifactorial assay for cancer detection

InactiveUS20050069963A1Rapid and early detectionPeptide/protein ingredientsMicrobiological testing/measurementAnti her2Anti-MUC-1
Provided are methods for the rapid detection of ovarian cancer. The methods employ a multiplex immunoassay to detect levels of two or more of the markers EGF, G-CSF, IL-6, IL-8, CA-125, VEGF, MCP-1, anti-IL6, anti-IL8, anti CA-125, anti-c-myc, anti-p53, anti-CEA, anti-CA 15-3, anti-MUC-1, anti-survivin, anti-bHCG, anti-osteopontin, anti-PDGF, anti-Her2 / neu, anti-Akt1, anti-cytokeratin 19, cytokeratin 19, EGFR, CEA, kallikrein-8, M-CSF, FasL, ErbB2 and Her2 / neu in a sample of the patient's blood, where the presence of abnormal levels of two or more of the markers indicates the presence of ovarian cancer in the patient. An array also is provided to quantitate levels of these markers in a patient's blood. Also provided is a method of predicting onset of clinical ovarian cancer comprising determining the change in concentration over time of two or more of anti-Her2 / neu, anti-MUC-1, anti-c-myc, anti-p53, anti-CA-125, anti-CEA, anti-CA 72-4, anti-PDGFRα, IFNγ, IL-6, IL-10, TNFα, MIP-1α, MIP-1β, EGFR and Her2 / neu in a patient's blood.
Owner:UNIVERSITY OF PITTSBURGH

Methods and compositions for the diagnosis for early hepatocellular carcinoma

ActiveUS20080038736A1Microbiological testing/measurementBiological testingCyclin D1Early Hepatocellular Carcinoma
Methods and compositions are provide to allow discrimination of dysplastic nodules from early HCC nodules. More specifically, it has been determined that TERT, GPC3, gankyrin, survivin, TOP2A, LYVE1, Ecadherin, IGFBP3, PDGFRA, TGFA, cyclin D1 and HGF are differentially expressed in HCC as compared to normal liver cells and liver cells that have dysplastic, non-cancerous nodules.
Owner:MT SINAI SCHOOL OF MEDICINE

Survivin-derived peptides and use thereof

MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-gamma-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses hereof.
Owner:SURVAC

LNA oligonucleotides and the treatment of cancer

The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5′-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3′, and preferably of the general formula 5′-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3′, wherein capital letters designate an LNA nucleotide analogue selected from β-D-oxy-LNA, β-D-thio-LNA, β-D-amino-LNA and α-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumour development in vivo. The LNA oligonucleotides are superior to other LNA oligonucletides targeting Surviving mRNA measured by functional read outs such as apoptosis induction and proliferation inhibition, and is potent in down-regulating Survivin mRNA and protein in transfected cancer cell lines, and induce apoptosis in combination with Taxol superior compared to other LNA oligonucleotides.
Owner:ENZON PHARM INC

Guggulsterone: an inhibitor of nuclear factor - kappaB and IkappaBalpha kinase activation and uses thereof

The present invention provides an inhibitor of NF-κB, guggulsterone and its analogs. Guggulsterone suppresses NF-κB activation induced by TNF, phorbol ester, okadaic acid, cigarette smoke, H2O2 and IL-1β, as well as constitutive NF-κB activation expressed in most tumor cells. One mechanism by which guggulsterone inhibits activation of NF-κB is through suppression of IκBα phosphorylation and IκBα degradation. NF-κB-dependent gene transcription is modulated by guggulsterone and its analogs. In particular, induction by TNF, TNFR1, TRADD, TRAF2, NIK and IKK, is modulated by guggulsterone and its analogs. In addition, guggulsterone decreased the expression of genes involved in anti-apoptosis (IAP1, XIAP, Bfl-1 / A1, bcl-2, cFLIP, survivin), proliferation (cyclin D1, c-myc) and metastasis (MMP-9, COX2 and VEGF).
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Novel and powerful mhc-class ii peptides derived from survivin

The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Owner:IMMATICS BIOTECHNOLOGIES GMBH

Method for effectively culturing tumor infiltrating lymphocytes (TILs)

InactiveCN102174469AShorter hospital stayReduce the burden of hospitalizationBlood/immune system cellsAntineoplastic agentsClinical efficacyApoptosis Regulatory Proteins
The invention discloses a method for effectively culturing tumor infiltrating lymphocytes (TILs). The method comprises the following steps: extracting mononuclear cells from the pectoral ascite or tumor tissue of a patient, washing, inoculating into a culture bottle coated with recombinant human fibrin and cluster-of-differentiation-3 antibody, culturing for 24 hours, adding interleukin II, then using a serum-free culture medium containing the interleukin II and the supernatant pectoral ascite to enlarge and subculture every two or three days, and adding apoptosis-regulated protein survivin and mucoprotein-1 on the twelveth or thirteenth day to activate the killing activity; and harvesting cells on the fourteenth day. By adopting the method, the culture time, which is only 14 days, is greatly shortened, so that the hospital stays of the patient can be greatly shortened and the hospital burden of the patient can be reduced. Meanwhile, the problems that the cell proliferation speed is low and the proliferation ratio is low can be solved, thus the number of the cultured cells can meet the clinical requirement. The cultured TILs has strong cell specificity so as to enhance the clinical curative effect.
Owner:宋鑫 +1

Cancer-specific promoters

The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-specific and ovarian cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of fatty acid synthase and claudin 4 promoters, particularly in combination with a two-step transcription amplification sequence and / or a post-transcriptional control sequence. Two ovarian cancer-specific sequences utilize specific regions of hTERT and survivin promoters, particularly in combination with a two-step transcription amplification sequence and / or a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Survivin Peptides As Cancer Vaccines

ActiveUS20090041732A1Improved human cell mediated immune responseImprove survivalBiocidePeptide/protein ingredientsCancer cellCancer research
Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual.
Owner:HEALTH RES INC

Survivin-derived peptides and use thereof

ActiveUS20040176573A1Easy to filterIncrease the immuogenicity of survivin-derived peptidesPeptide/protein ingredientsApoptosis related proteinsMHC class IWilms' tumor
MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-gamma-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses hereof.
Owner:SURVAC

Detection of survivin in the biological fluids of cancer patients

The present invention includes a method for diagnosing cancer comprising detecting the presence of survivin in the biological fluid of a patient. The present invention also provides kits comprising one or more agents that detect survivin polypeptide or survivin nucleic acid and a container for collecting biological fluid for testing.
Owner:YALE UNIV

Survivin peptide vaccine

The present invention relates to a therapeutic vaccine comprising one or more survivin polypeptide fragments. The vaccine can be used for prophylactic, ameliorating and / or curative treatment of e.g. cancer diseases. The invention further relates to methods of combination treatment.
Owner:SURVAC

Kit for jointly detecting breast cancer 21 genes and preparation method of kit

InactiveCN104004844AEasy to operateShorten detection experiment timeMicrobiological testing/measurementSingle sampleBAG1
The invention discloses a kit for jointly detecting breast cancer 21 genes. A PCR (polymerase chain reaction) amplification primer consists of 21 primer pairs, and can be used for jointly detecting 21 gene-related expression quantities: Ki67, STK15, Survivin, CCNB1, MYBL2, MMP11, CTSL2, GRB7, HER2, GSTM1, CD68, BAG1, ER, PGR, BCL2, SCUBE2, ACTB, GAPDH, PRLPO, GUS, and TFRC. Output fragments of the 21 pairs of primers related in the invention are smaller than 100bp, so that PCR efficiency after reverse transcription of mRNA (messenger ribonucleic acid) extracted by a paraffin specimen is greatly improved, all primers of 21 genes are premixed, and time and labor for designing and synthesizing 21 pairs of genes by an experimenter are saved; the corresponding primers of the 21 genes are not needed to be added for premixing in mother liquor, and therefore, errors of reaction holes are greatly reduced. The kit disclosed by the invention is simple to operate, and capable of detecting on a quantitative PCR instrument by only adding a template, so that detection experimental time is greatly shortened. The kit disclosed by the invention is applicable to a single sample and multiple samplers, so that results can be quickly obtained, and therefore, scientific research and clinical detection requirements can be satisfied very well.
Owner:杭州美中疾病基因研究院有限公司

Survivin-directed RNA interference-compositions and methods

InactiveUS20060276423A1Poor prognosis of survivalHigh sensitivityBiocideOrganic active ingredientsDiseaseDNA
The present invention is directed to compositions and methods for inhibiting the expression of survivin in cells expressing survivin. The invention is also directed to methods of treating conditions associated with elevated survivin, such as hyperproliferative disorders. More particularly, the invention is directed to inhibition of survivin expression using short interfering RNAs (si-RNAs) or through administration of DNA sequences yielding the expression of short hairpin RNAs (sh-RNAs).
Owner:ALTURA RACHEL +2

Use of high efficiency siRNA for preparing tumor migration inhibition drug

The invention belongs to the biological medicine field, in particular relating to the use of a high efficiency small interfering RNA for preparing a tumor migration inhibition drug. The high efficiency small interfering RNA can silence the expression of survivin, change the adhesive force of breast cancer, gastric cancer and liver cancer cells against IV collagen, and inhibit the migrating ability of the breast cancer, gastric cancer and liver cancer cells at two-and three-dimensional levels. The small interfering RNA can also prepare the drug for inhibiting the tumor migration.
Owner:YICHUN UNIVERSITY

Recombinant oncolytic gene-adenovirus targeting cancer and construction method and application of recombinant oncolytic gene-adenovirus

The invention discloses a recombinant oncolytic gene-adenovirus targeting cancer, and the recombinant oncolytic gene-adenovirus is Ad-sp-E1A-delta E1B-VGLL4. The recombinant oncolytic gene-adenovirusAd-sp-E1A-delta E1B-VGLL4 is driven by a survivin promoter to drive a virus E1A gene, an E1B gene region is knocked out off the virus genome at the same time, and a VGLL4 expression frame fragment isinserted on the basis. The invention also discloses a construction method and application in preparing drugs for treating cancer of the recombinant oncolytic gene-adenovirus Ad-sp-E1A-delta E1B-VGLL4.The recombinant oncolytic gene-adenovirus Ad-sp-E1A-delta E1B-VGLL4 of the invention specifically replicates in cancer cells with the aid of an adenovirus vector, and achieves good therapeutic effects in anticancer tests.
Owner:SHANGHAI YUANSONG BIOTECHNOLOGY CO LTD

DNA vaccines against tumor growth and methods of use thereof

A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a DNA construct operably encoding a cancer-associated Inhibitor of Apoptosis-family protein and an immunoactive gene product, such as a cytokine or a ligand for a natural killer cell surface receptor, in a pharmaceutically acceptable carrier. A preferred cytokine is CCL21. Preferred ligands for a natural killer cell surface receptor include human MICA, human MICB, human ULBP1, human ULBP2, and human ULBP3. The cancer-associated Inhibitor of Apoptosis (IAP)-family protein is preferably a survivin protein or livin protein. Method of inhibiting tumor growth by administering the vaccine of the invention to a mammal is also described.
Owner:THE SCRIPPS RES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products